With positive PhIII data, Merck sets up a blockbuster attempt to overthrow Pfizer's reigning Prevnar 13
Merck is nearing the end of a years-long effort to dethrone Pfizer’s megablockbuster pneumococcal conjugate vaccine, Prevnar 13.
Straying away from its cash cow Keytruda …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.